weight loss

News

Eli Lilly has announced that orforglipron (Foundayo) is now available to be prescribed for eligible adults via private prescription.

R&D

GLP-1 RA medicine has transformed treatment of metabolic diseases such as obesity and diabetes. We spoke with China's CORXEL about theirs.

Patients

What happens if GLP-1s work too well?

Patients

Deep Dive editor Eloise McLennan reports on Novo Nordisk's inaugural Weight Talks Summit in London.

News

The US FDA has approved a fourth product via its new National Priority Voucher Programme - a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy.

R&D

In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.